At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 59 enrolled
Drug / intervention
Imsidolimab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis
In Brief
A Phase 2 clinical trial evaluating Imsidolimab and Placebo for Palmoplantar Pustulosis. Completed, enrolled 59 participants across 39 sites in 4 countries.
Detailed Summary
A study to evaluate the efficacy and safety, and pharmacokinetic (PK) profile of multiple doses of imsidolimab (ANB019) in adults with palmoplantar pustulosis (PPP)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPalmoplantar Pustulosis
CountriesCanada, Germany, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartMay 2019
Primary CompletionApr 2021
TodayJul 2026
First PostedAug 16, 2018
Enrollment StartMay 20, 2019
Primary CompletionApr 23, 2021
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 7.9 years ago
Interventions
Imsidolimabbiological
Administered by subcutaneous injection once a month
Placebodrug
Administered by subcutaneous injection once a month